about
Prevalence of Positive Diabetes-Associated Autoantibodies among Type 2 Diabetes and Related Metabolic and Inflammatory Differences in a Sample of the Bulgarian PopulationPhenotypes Determined by Cluster Analysis in Moderate to Severe Bronchial Asthma.Increased kallistatin levels in patients with obesity and prediabetes compared to normal glucose tolerance.Myostatin and carbohydrate disturbances.Treg/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients.Cartilage oligomeric protein, matrix metalloproteinase-3, and Coll2-1 as serum biomarkers in knee osteoarthritis: a cross-sectional study.Reduced soluble Toll-like receptors 2 in type 2 diabetes.Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune diabetes.Alterations in cytokine gene expression profile in colon mucosa of Inflammatory Bowel Disease patients on different therapeutic regimens.Increased peroxiredoxin 4 levels in patients with prediabetes compared to normal glucose tolerance subjects.Abstracts from the 3rd International Severe Asthma Forum (ISAF).Abstracts from the 10th C1-inhibitor deficiency workshop.Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF).Th17 cells in Bulgarian children with chronic obstructive lung diseasesCultured Cells Isolated from CNS Indolent B-Cell Lymphoma Have Characteristics of Mesenchymal Stem Cells: A Clinical Case and Scientific ResearchHigher levels of IL-18 in patients with prediabetes compared to obese normoglycaemic controlsHigher levels of thioredoxin interacting protein (TXNIP) in patients with prediabetes compared to obese normoglycemic subjectsSerum trefoil factor 3 predicts disease activity in patients with ulcerative colitisCeliac-Related Autoantibodies and IL-17A in Bulgarian Patients with Dermatitis Herpetiformis: A Cross-Sectional StudyLactobacilli Supplemented with Larch Arabinogalactan and Colostrum Stimulates an Immune Response towards Peripheral NK Activation and Gut Tolerance
P50
Q33717570-AA12395F-39AD-4600-AA83-7CD6B5FCA333Q38681014-0E991A6D-7182-4E50-BD42-CDF74DA05EC7Q38838756-DB77E073-684F-4147-8BE6-A6FEE7AD8FE7Q39645526-B005A85F-7CBF-4FC8-8A5C-BBEC27761BE1Q41519827-481969A8-5694-40F4-B6FE-50C7A0C5B685Q47375322-ABDE7012-158B-44E3-8B72-0FADD518C89FQ47379705-E71F9DCC-D70F-40F4-919D-68FCA86938A8Q50021277-A619D79E-7704-4D52-88F3-95959C24FAACQ51190420-C28A261A-E31B-485D-B94A-27C4503A3FD7Q51702089-B012EEAC-2D22-4CF2-B245-E7A6D86078BBQ54912962-A69FC2C1-ACB1-4AC1-8CDD-F8B99F57316EQ55116370-621DE0E0-2FB1-4FEE-9E40-E029794A4AE8Q55461242-006E90D1-71FC-40E6-B0EE-E49A7C0336E8Q57151003-682DC74B-257A-486D-BF19-0122E3277A9EQ90817071-DA74CF2A-D33F-43A5-B4D2-8FDF01A0F9B7Q90997601-352D02EF-94E0-4ED9-BB37-E15CA3C4E5EAQ91039871-9338A1FA-4AAF-44A3-B1C4-ACA16BED3A14Q91346327-76003104-213B-4521-AAAD-AD4DFB68CCBAQ92082653-6EEBE5D9-887B-4C33-95FA-133A2B017310Q96226714-B76995CA-C942-45CB-852F-0E992469F20B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tsvetelina Velikova
@ast
Tsvetelina Velikova
@en
Tsvetelina Velikova
@es
Tsvetelina Velikova
@nl
Tsvetelina Velikova
@sl
type
label
Tsvetelina Velikova
@ast
Tsvetelina Velikova
@en
Tsvetelina Velikova
@es
Tsvetelina Velikova
@nl
Tsvetelina Velikova
@sl
prefLabel
Tsvetelina Velikova
@ast
Tsvetelina Velikova
@en
Tsvetelina Velikova
@es
Tsvetelina Velikova
@nl
Tsvetelina Velikova
@sl
P106
P1153
55987966500
P31
P496
0000-0002-0593-1272